Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Alzheimer's disease drug development pipeline: 2022
Jeffrey L. Cummings, Garam Lee, Pouyan Nahed, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 526

Showing 1-25 of 526 citing articles:

2023 Alzheimer's disease facts and figures

Alzheimer s & Dementia (2023) Vol. 19, Iss. 4, pp. 1598-1695
Open Access | Times Cited: 1968
Alzheimer's disease drug development pipeline: 2018
Jeffrey L. Cummings, Garam Lee, Aaron Ritter, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2018) Vol. 4, Iss. 1, pp. 195-214
Open Access | Times Cited: 675
Emerging diagnostics and therapeutics for Alzheimer disease
Wade Self, David M. Holtzman
Nature Medicine (2023) Vol. 29, Iss. 9, pp. 2187-2199
Closed Access | Times Cited: 182
Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation
Yijun Chen, Yang Yu
Journal of Neuroinflammation (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 143
Precuneus magnetic stimulation for Alzheimer’s disease: a randomized, sham-controlled trial
Giacomo Koch, Elias Paolo Casula, Sonia Bonnı̀, et al.
Brain (2022) Vol. 145, Iss. 11, pp. 3776-3786
Open Access | Times Cited: 141
Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
Li‐Kai Huang, Yi‐Chun Kuan, Ho-Wei Lin, et al.
Journal of Biomedical Science (2023) Vol. 30, Iss. 1
Open Access | Times Cited: 125
Anti-amyloid antibody therapies in Alzheimer’s disease
Robert Perneczky, Frank Jessen, Timo Grimmer, et al.
Brain (2023) Vol. 146, Iss. 3, pp. 842-849
Open Access | Times Cited: 116
Glutamate and GABA in Microglia-Neuron Cross-Talk in Alzheimer’s Disease
Grzegorz A. Czapski, Joanna B. Strosznajder
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11677-11677
Open Access | Times Cited: 106
The amyloid cascade hypothesis: an updated critical review
Kasper P. Kepp, Nikolaos K. Robakis, Poul Flemming Høilund‐Carlsen, et al.
Brain (2023) Vol. 146, Iss. 10, pp. 3969-3990
Open Access | Times Cited: 106
Biomarkers in Alzheimer’s disease: role in early and differential diagnosis and recognition of atypical variants
Bruno Dubois, Christine A. F. Von Arnim, Nerida Burnie, et al.
Alzheimer s Research & Therapy (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 82
Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging
Rioghna R. Pittock, Jeremiah A. Aakre, Anna Castillo, et al.
Neurology (2023) Vol. 101, Iss. 19
Open Access | Times Cited: 81
Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Adam L. Boxer, Reisa A. Sperling
Cell (2023) Vol. 186, Iss. 22, pp. 4757-4772
Open Access | Times Cited: 71
The Role of Glymphatic System in Alzheimer’s and Parkinson’s Disease Pathogenesis
Francesca R. Buccellato, Marianna D’Anca, María Serpente, et al.
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2261-2261
Open Access | Times Cited: 68
The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint
Linus Jönsson, Anders Wimo, Ron Handels, et al.
The Lancet Regional Health - Europe (2023) Vol. 29, pp. 100657-100657
Open Access | Times Cited: 67
Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer’s disease? From preclinical studies to the clinical trials
Neha Basheer, Tomáš Smolek, Md. Imtaiyaz Hassan, et al.
Molecular Psychiatry (2023) Vol. 28, Iss. 6, pp. 2197-2214
Open Access | Times Cited: 56
Roles of Oxidative Stress in Synaptic Dysfunction and Neuronal Cell Death in Alzheimer’s Disease
Germán Plascencia‐Villa, George Perry
Antioxidants (2023) Vol. 12, Iss. 8, pp. 1628-1628
Open Access | Times Cited: 55
Biomedical knowledge graph learning for drug repurposing by extending guilt-by-association to multiple layers
Dongmin Bang, Sangsoo Lim, Sangseon Lee, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 53
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update
Kevin McFarthing, Susan Buff, Gary Rafaloff, et al.
Journal of Parkinson s Disease (2023) Vol. 13, Iss. 4, pp. 427-439
Open Access | Times Cited: 52
Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
Anne‐Cathrine S. Vogt, Gary T. Jennings, Mona O. Mohsen, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3895-3895
Open Access | Times Cited: 50
Customized Intranasal Hydrogel Delivering Methylene Blue Ameliorates Cognitive Dysfunction against Alzheimer's Disease
Yujing Liu, Yun Tan, Guopan Cheng, et al.
Advanced Materials (2024) Vol. 36, Iss. 19
Closed Access | Times Cited: 30
The interaction between ageing and Alzheimer's disease: insights from the hallmarks of ageing
Yuqing Liu, Yejun Tan, Zheyu Zhang, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 26
Neuroprotective and anti‐inflammatory effects of curcumin in Alzheimer's disease: Targeting neuroinflammation strategies
Elena Azzini, Sheila I. Peña‐Corona, Héctor Hernández‐Parra, et al.
Phytotherapy Research (2024) Vol. 38, Iss. 6, pp. 3169-3189
Closed Access | Times Cited: 25
Alzheimer disease blood biomarkers: considerations for population-level use
Michelle M. Mielke, Nicole R. Fowler
Nature Reviews Neurology (2024) Vol. 20, Iss. 8, pp. 495-504
Closed Access | Times Cited: 24
Distinct tau and alpha-synuclein molecular signatures in Alzheimer’s disease with and without Lewy bodies and Parkinson’s disease with dementia
Bram van der Gaag, Natasja A. C. Deshayes, John J. P. Brevé, et al.
Acta Neuropathologica (2024) Vol. 147, Iss. 1
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top